CompanyMBRXNasdaqHouston, TX

Moleculin Biotech, Inc.

Moleculin Biotech develops Annamycin, an anthracycline in Phase 2/3 development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Stories only

SEC EDGAR ClinicalTrials.gov moleculin.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

Moleculin closes Part A enrollment in MIRACLE AML trial at 89, one subject still in screening

Sep 29Trial updateMoleculin Biotech, Inc.

August 2026

Moleculin Biotech closes $9.3 million public offering with Roth Capital as placement agent

Aug 3PartnershipMoleculin Biotech, Inc.

July 2026

Moleculin reports 37% blinded CRc in venetoclax-failed AML patients from MIRACLE trial

Jul 31Clinical readoutMoleculin Biotech, Inc.venetoclax

June 2026

Moleculin reports interim MIRACLE data showing higher remission with Annamycin

Jun 30Clinical readoutMoleculin Biotech, Inc.

Moleculin closes Part A enrollment in MIRACLE AML trial at 89, one subject still in screening

Moleculin Biotech increases ATM stock offering size to $19.7 million

Moleculin reports positive interim MIRACLE data, keeps trial timeline on track

Moleculin prices $9.3M offering of stock and warrants at $0.75/share

Moleculin Biotech closes $9.3 million public offering with Roth Capital as placement agent

Moleculin reports 37% blinded CRc in venetoclax-failed AML patients from MIRACLE trial

Moleculin reports interim MIRACLE data showing higher remission with Annamycin